Lifesciences psychedelics biotech Psyence Group Inc. (OTCQB: PSYGF) recently exported purified pharmaceutical-grade psilocybin mushroom extract from its licensed and certified production facility in Southern Africa to its Contract Development & Manufacturing Organization (CDMO) partner in the UK.

In turn, the Good Manufacturing Practice (GMP)-compliant pharma services company will use the imported psilocybin extract to develop standardized pharma-grade psilocybin and psilocin extracts, which will be formulated into a final product and seek regulatory approval.

“We are incredibly proud to be one of the …

Full story available on Benzinga.com